JP2015511625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511625A5 JP2015511625A5 JP2015502438A JP2015502438A JP2015511625A5 JP 2015511625 A5 JP2015511625 A5 JP 2015511625A5 JP 2015502438 A JP2015502438 A JP 2015502438A JP 2015502438 A JP2015502438 A JP 2015502438A JP 2015511625 A5 JP2015511625 A5 JP 2015511625A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ccl7
- composition according
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 12
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims 12
- 210000000440 neutrophil Anatomy 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 6
- 238000009825 accumulation Methods 0.000 claims 5
- 208000038016 acute inflammation Diseases 0.000 claims 5
- 230000006022 acute inflammation Effects 0.000 claims 5
- 206010069351 acute lung injury Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 3
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 3
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 101150093826 par1 gene Proteins 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 102100026236 Interleukin-8 Human genes 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1205739.4A GB201205739D0 (en) | 2012-03-30 | 2012-03-30 | Treatment of acute inflammation in the respiratory tract |
| GB1205739.4 | 2012-03-30 | ||
| PCT/GB2013/050665 WO2013144563A1 (en) | 2012-03-30 | 2013-03-15 | Treatment of acute inflammation in the respiratory tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511625A JP2015511625A (ja) | 2015-04-20 |
| JP2015511625A5 true JP2015511625A5 (enExample) | 2016-05-12 |
Family
ID=46160077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015502438A Pending JP2015511625A (ja) | 2012-03-30 | 2013-03-15 | 呼吸器における急性炎症の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150079105A1 (enExample) |
| EP (1) | EP2830657A1 (enExample) |
| JP (1) | JP2015511625A (enExample) |
| GB (1) | GB201205739D0 (enExample) |
| WO (1) | WO2013144563A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6944701B2 (ja) * | 2016-10-21 | 2021-10-06 | 国立大学法人山口大学 | ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物 |
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| AU2020254610A1 (en) | 2019-04-01 | 2021-11-18 | Applied Therapeutics Inc. | Inhibitors of aldose reductase |
| CN113966396A (zh) | 2019-05-07 | 2022-01-21 | 迈阿密大学 | 遗传性神经病和相关障碍的治疗和检测 |
| CN114502164B (zh) * | 2019-05-22 | 2024-01-26 | 石药集团中奇制药技术（石家庄）有限公司 | 杂环化合物及其盐的应用 |
| EP4125909A1 (en) * | 2020-03-31 | 2023-02-08 | Applied Therapeutics Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
| US20230165838A1 (en) * | 2020-05-06 | 2023-06-01 | Dimerix Bioscience Ltd. | Treatment for acute respiratory distress syndrome |
| WO2021222971A1 (en) * | 2020-05-06 | 2021-11-11 | Dimerix Bioscience Ltd | Treatment for virus induced acute respiratory distress syndrome |
| KR20250133491A (ko) * | 2024-02-28 | 2025-09-08 | 재단법인 오송첨단의료산업진흥재단 | 인간 ccl7에 결합하는 신규한 항체 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| JP4531132B2 (ja) | 1995-06-02 | 2010-08-25 | ギリード・サイエンシズ・インコーポレーテッド | 増殖因子に対する高親和性オリゴヌクレオチドリガンド |
| US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| AU2002357770B2 (en) * | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
| US7964194B2 (en) * | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| US20070238755A1 (en) * | 2005-12-20 | 2007-10-11 | Martin Hauer-Jensen | Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue |
| EP2709630A4 (en) * | 2011-05-12 | 2014-10-22 | UNIVERSITé LAVAL | PAR1 HEMMER FOR USE IN THE TREATMENT OR PREVENTION OF PARAMYXOVIRIDAE INFECTIONS |
-
2012
- 2012-03-30 GB GBGB1205739.4A patent/GB201205739D0/en not_active Ceased
-
2013
- 2013-03-15 WO PCT/GB2013/050665 patent/WO2013144563A1/en not_active Ceased
- 2013-03-15 US US14/389,718 patent/US20150079105A1/en not_active Abandoned
- 2013-03-15 EP EP13711113.4A patent/EP2830657A1/en not_active Withdrawn
- 2013-03-15 JP JP2015502438A patent/JP2015511625A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hattori et al. | Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: novel therapeutic implications and challenges | |
| JP2011144201A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2011157378A5 (enExample) | ||
| JP2016523863A5 (enExample) | ||
| JP2014074046A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| Wunderink et al. | Adjunctive therapy in community-acquired pneumonia | |
| JP2013519675A5 (enExample) | ||
| JP2011503012A5 (enExample) | ||
| NZ709997A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| EP4591936A3 (en) | Treatment of respiratory diseases | |
| JP2010500291A5 (enExample) | ||
| JP2016534996A5 (enExample) | ||
| WO2010144336A3 (en) | Methods for treating chronic kidney disease | |
| JP2020507587A5 (enExample) | ||
| JP2013525310A5 (enExample) | ||
| MX2018014425A (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| RU2007107915A (ru) | Лекарственные средства для лечения хронического респираторного заболевания | |
| JP2007506681A5 (enExample) | ||
| JP2014520874A5 (enExample) | ||
| JP2014520854A5 (enExample) | ||
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| JP2011012060A5 (enExample) |